Clinical and biological characteristics of myelodysplastic syndromes with nulisomy Y by FISH

被引:0
|
作者
GarciaIsidoro, M
Tabernero, MD
Najera, ML
Garcia, JL
Hernandez, JM
Duran, A
SanMiguel, JF
Orfao, A
机构
[1] UNIV HOSP, HEMATOL LAB, SERV CITOMETRIA, SALAMANCA 37007, SPAIN
[2] UNIV SALAMANCA, DEPT MED, SERV CITOMETRIA, E-37008 SALAMANCA, SPAIN
关键词
cytogenetics; FISH; myelodysplastic syndromes; nulisomy Y;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objective. In the present study we analyzed the incidence of nulisomy Y by fluorescence in situ hybridization in a group of 24 males diagnosed with myelodysplastic syndromes (MDS). We explored the relationship between this chromosome abnormality and other clinical and biological disease characteristics. Methods. Loss of chromosome Y was present in 7 out of the 24 males analyzed (29%); the number of cells carrying this chromosome aberration ranged between 19% and 90%. From the clinico-biological point of view, the group of patients with nulisomy Y showed a higher incidence of RA and RAS FAB subtypes (p=0.04), a lower WBC count (p=0.04), a lower proportion of blast cells both in PB (p=0.009) and BM (p=0.06) associated with a decreased myeloid/erythroid ratio (p=0.01). Results. No clear association was detected between loss of chromosome Y and other numerical chromosome abnormalities involving chromosomes 7 and 8. In contrast, 2 out of the 7 cases with loss of chromosome Y also displayed monosomy 1 by FISH. However, the use of appropriate dual stainings showed that these two abnormalities were present in different cell populations (that is, they never coexisted in the same cell population), which supports the notion of the existence of clonal heterogeneity in MDS patients. Interpretation and Conclusions. From the prognostic point of view, MDS patients with loss of chromosome Y displayed a higher survival rate, although these differences did not reach statistical significance. (C) 1997, Ferrata Storti Foundation.
引用
收藏
页码:537 / 541
页数:5
相关论文
共 50 条
  • [21] Clinical, immunophenotypic, and cytogenetic characteristics of high-grade myelodysplastic syndromes with CD41-positive progenitor cells
    Ogata, Kiyoyuki
    Sei, Kazuma
    Kawahara, Naoya
    Ogata, Mika
    Yamamoto, Yumi
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2023, 104 (01) : 98 - 107
  • [22] Combining gene variants with clinical characteristics improves outcome prediction in Chinese patients with myelodysplastic syndromes
    Yu, Yan
    Zhang, Tongtong
    Bao, Xiebing
    Wang, Qinrong
    Zhang, Ling
    Hong, Yang
    Zeng, Zhao
    Shen, Hongjie
    Wu, Depei
    Pan, Jinlan
    Liu, Hong
    Chen, Suning
    Sun, Aining
    LEUKEMIA & LYMPHOMA, 2020, 61 (04) : 919 - 926
  • [23] CLINICAL CHARACTERISTICS OF JAPANESE PATIENTS WITH PRIMARY MYELODYSPLASTIC SYNDROMES - A COOPERATIVE STUDY BASED ON 838 CASES
    OGUMA, S
    YOSHIDA, Y
    UCHINO, H
    MAEKAWA, T
    NOMURA, T
    MIZOGUCHI, H
    LEUKEMIA RESEARCH, 1995, 19 (03) : 219 - 225
  • [24] Cytogenetic characteristics of patients with signs and symptoms of myelodysplastic syndromes in the State of Para, Brazil
    Pinto, Giovanny Reboucas
    Overal, David James
    de Moraes, Leopoldo Silva
    Van Den Berg, Ana Virginia
    Rodrigues Lemos, Jose Alexandre
    Cardoso Smith, Marilia de Arruda
    Burbano, Rommel Rodriguez
    GENETICS AND MOLECULAR RESEARCH, 2005, 4 (01) : 18 - 30
  • [25] Incidence and characteristics of lymphoid malignancies in untreated myelodysplastic syndromes
    Florensa, L
    Vallespi, T
    Woessner, S
    Domingo, A
    Crespo, N
    Rozman, M
    Aguilar, JL
    Irriguible, D
    Zarco, A
    Milla, F
    Feliu, E
    LEUKEMIA & LYMPHOMA, 1996, 23 (5-6) : 609 - 612
  • [26] Novel Therapies for Unmet Clinical Needs in Myelodysplastic Syndromes
    Cassanello, Giulio
    Pasquale, Raffaella
    Barcellini, Wilma
    Fattizzo, Bruno
    CANCERS, 2022, 14 (19)
  • [27] The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes
    Abou Zahr, Abdallah
    Aldin, Ehab Saad
    Barbarotta, Lisa
    Podoltsev, Nikolai
    Zeidan, Amer M.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (09) : 1019 - 1036
  • [28] CLINICAL USE OF GROWTH-FACTORS IN THE MYELODYSPLASTIC SYNDROMES
    STEIN, RS
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1994, 307 (05) : 360 - 367
  • [29] The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes
    Palumbo, Antonio
    Freeman, John
    Weiss, Lilia
    Fenaux, Pierre
    EXPERT OPINION ON DRUG SAFETY, 2012, 11 (01) : 107 - 120
  • [30] Graphical representation of clinical outcomes for patients with myelodysplastic syndromes
    Steensma, David P.
    LEUKEMIA & LYMPHOMA, 2016, 57 (01) : 17 - 20